This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (94)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Complementary and Alternative Medicine  • Adverse Effects  • Alert me on articles by topic

John S. Markowitz, PharmD; Jennifer L. Donovan, PhD; C. Lindsay DeVane, PharmD; Robin M. Taylor, BS; Ying Ruan, MD; Jun-Sheng Wang, MD, PhD; Kenneth D. Chavin, MD, PhD

JAMA. 2003;290:1500-1504.

Context  St John's wort is a popular herbal product used to treat depression but it has been implicated in drug interactions.

Objective  To assess the potential of St John's wort administration to alter the activity of the cytochrome P450 (CYP) enzymes extensively involved in drug metabolism.

Design, Setting, and Participants  Open-label crossover study with fixed treatment order conducted March 2002 to February 2003 in a US general clinical research center involving 12 healthy volunteers (6 men and 6 women) aged 22 to 38 years before and after 14 days of administration of St John's wort.

Intervention  Participants were given probe drugs (30 mg of dextromethorphan and 2 mg of alprazolam) to establish baseline CYP 3A4 and CYP 2D6 activity. After a minimum 7-day washout period, participants began taking one 300-mg tablet 3 times per day. After 14 days of St John's wort administration, participants were given the probe drugs along with 1 St John's wort tablet to establish postadministration CYP activity; the St John's wort dosing regimen was continued for 48 hours.

Main Outcome Measures  Changes in plasma pharmacokinetics of alprazolam as a probe for CYP 3A4 activity and the ratio of dextromethorphan to its metabolite, dextrorphan, in urine as a probe for CYP 2D6 activity.

Results  A 2-fold decrease in the area under the curve for alprazolam plasma concentration vs time (P<.001) and a 2-fold increase in alprazolam clearance (P<.001) were observed following St John's wort administration. Alprazolam elimination half-life was shortened from a mean (SD) of 12.4 (3.9) hours to 6.0 (2.4) hours (P<.001). The mean (SD) urinary ratio of dextromethorphan to its metabolite was 0.006 (0.010) at baseline and 0.014 (0.025) after St John's wort administration (P = .26).

Conclusions  A 14-day course of St John's wort administration significantly induced the activity of CYP 3A4 as measured by changes in alprazolam pharmacokinetics. This suggests that long-term administration of St John's wort may result in diminished clinical effectiveness or increased dosage requirements for all CYP 3A4 substrates, which represent at least 50% of all marketed medications.

Author Affiliations: Department of Pharmaceutical Sciences (Dr Markowitz), Department of Psychiatry and Behavioral Sciences (Drs Donovan, DeVane, Ruan, and Wang and Ms Taylor), and Department of Surgery, Division of Transplantation (Dr Chavin), Medical University of South Carolina, Charleston.

RELATED ARTICLE

Drugs Alias Dietary Supplements
Catherine D. DeAngelis and Phil B. Fontanarosa
JAMA. 2003;290(11):1519-1520.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Hypericum perforatum (St John's Wort) for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Randomized Controlled Trial
Weber et al.
JAMA 2008;299:2633-2641.
ABSTRACT | FULL TEXT  

Dietary Supplements: Clinical Implications for Dentistry
Radler
Journal of the American Dental Association 2008;139:451-455.
ABSTRACT | FULL TEXT  

Vitamin and Mineral Supplement Use Among US Adults After Cancer Diagnosis: A Systematic Review
Velicer and Ulrich
JCO 2008;26:665-673.
ABSTRACT | FULL TEXT  

Lack of Pharmacokinetic Interaction Between St. John's Wort and Prednisone
Bell et al.
The Annals of Pharmacotherapy 2007;41:1819-1824.
ABSTRACT | FULL TEXT  

Complementary Therapies and Integrative Oncology in Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Cassileth et al.
Chest 2007;132:340S-354S.
ABSTRACT | FULL TEXT  

Complementary, Holistic, and Integrative Medicine: St. John's Wort
Charrois et al.
Pediatr. Rev. 2007;28:69-72.
FULL TEXT  

Guidelines for Monitoring and Management of Pediatric Patients During and After Sedation for Diagnostic and Therapeutic Procedures: An Update
American Academy of Pediatrics et al.
Pediatrics 2006;118:2587-2602.
ABSTRACT | FULL TEXT  

An Overview of Psychotropic Drug-Drug Interactions
Sandson et al.
Psychosomatics 2005;46:464-494.
ABSTRACT | FULL TEXT  

The potential impact of the use of homeopathic and herbal remedies on monitoring the safety of prescription products
Woodward
Hum Exp Toxicol 2005;24:219-233.
ABSTRACT  

Natural Health Product Interactions with Medication
Boullata
Nutr Clin Pract 2005;20:33-51.
ABSTRACT | FULL TEXT  

Guideline Watch: Practice Guideline for the Treatment of Patients With Major Depressive Disorder, 2nd Edition
Fochtmann and Gelenberg
Focus 2005;3:34-42.
FULL TEXT  

MULTIPLE NIGHT-TIME DOSES OF VALERIAN (Valeriana officinalis) HAD MINIMAL EFFECTS ON CYP3A4 ACTIVITY AND NO EFFECT ON CYP2D6 ACTIVITY IN HEALTHY VOLUNTEERS
Donovan et al.
Drug Metab. Dispos. 2004;32:1333-1336.
ABSTRACT | FULL TEXT  

GREEN TEA (CAMELLIA SINENSIS) EXTRACT DOES NOT ALTER CYTOCHROME P450 3A4 OR 2D6 ACTIVITY IN HEALTHY VOLUNTEERS
Donovan et al.
Drug Metab. Dispos. 2004;32:906-908.
ABSTRACT | FULL TEXT  

Interaction of St John's wort with conventional drugs: systematic review of clinical trials
Mills et al.
BMJ 2004;329:27-30.
ABSTRACT | FULL TEXT  

Herbal Remedies in the United States: Potential Adverse Interactions With Anticancer Agents
Sparreboom et al.
JCO 2004;22:2489-2503.
ABSTRACT | FULL TEXT  

Potential Drug Interactions with St. John's Wort
JWatch Psychiatry 2003;2003:9-9.
FULL TEXT  

Potential Drug Interactions with St. John's Wort
JWatch General 2003;2003:4-4.
FULL TEXT  

Drugs Alias Dietary Supplements
DeAngelis and Fontanarosa
JAMA 2003;290:1519-1520.
FULL TEXT